# A Study of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection in Chinese Participants With Acute Gout

> **NCT06169891** · PHASE3 · UNKNOWN · sponsor: **Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.** · enrollment: 500 (estimated)

## Conditions studied

- Acute Gout

## Interventions

- **DRUG:** Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg
- **OTHER:** Placebo
- **DRUG:** Compound Betamethasone Injection
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06169891
- **Lead sponsor:** Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-12
- **Primary completion:** 2024-12
- **Final completion:** 2025-11
- **Target enrollment:** 500 (ESTIMATED)
- **Last updated:** 2023-12-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06169891

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06169891, "A Study of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection in Chinese Participants With Acute Gout". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06169891. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*